Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FSHR | P23945 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24749754 | 0.87 | RXFP1 (0.37) | LNPEPBRAFTSHRFSHRHRH3 | |
| SCHEMBL29344673 | 0.77 | MEN1 (0.38) | BRAFMEN1HPGDKMT2ANPSR1 | |
| SCHEMBL24750189 | 0.76 | SLC5A1 (0.36) | LNPEPACACB | |
| SCHEMBL24749691 | 0.73 | RXFP1 (0.41) | BRAFMEN1KMT2A | |
| SCHEMBL30768285 | 0.73 | RXFP1 (0.41) | BRAFMEN1KMT2A | |
| SCHEMBL24750237 | 0.73 | BRAF (0.42) | BRAFMEN1HPGDKMT2ANPSR1 | |
| SCHEMBL24749647 | 0.73 | MEN1 (0.34) | LNPEPMEN1HPGDKMT2ANPSR1 | |
| SCHEMBL31009433 | 0.73 | MEN1 (0.34) | LNPEPMEN1HPGDKMT2ANPSR1 | |
| SCHEMBL24749699 | 0.73 | LNPEP (0.32) | LNPEP | |
| SCHEMBL24750236 | 0.73 | RORC (0.35) | BRAFHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | LNPEP 3580/4885BRAF 1369/4885MEN1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.